Information Provided By:
Fly News Breaks for April 1, 2015
SRPT
Apr 1, 2015 | 15:18 EDT
Credit Suisse said a recent FDA workshop on dystrophin quantification left its view unchanged and the firm still believes dystrophin is a viable surrogate endpoint. The firm thinks Sarepta's DMD drug eteplirsen can be approved under accelerated approval with dystrophin and believes any additional work needed to satisfy the FDA would only cause a modest delay, though it adjusted its expectation for the launch of the drug by three months to Q3 2016 to account for the potential added work. Credit Suisse has an Outperform rating and $36 price target on Sarepta shares.
News For SRPT From the Last 2 Days
There are no results for your query SRPT